经皮CT引导微波消融治疗骨样骨瘤:单中心经验
本研究为单中心回顾性研究,纳入2021年1月至2023年5月连续59例接受经皮CT引导微波消融治疗的骨样骨瘤患者,平均年龄17.31±8.53岁;技术成功率和临床成功率均为96.6%,3个月随访时2例(3.4%)复发并经第二次微波消融成功处理,仅1例(1.7%)出现轻微并发症,无严重并发症。
要点
- CT引导经皮微波消融治疗骨样骨瘤的技术成功率和临床成功率均为96.6%。
- 术后疼痛视觉模拟评分(VAS)中位数从术前8.64±1.14降至术后第1个月0.63±0.98、第3个月0.41±1.02、第6个月0.15±0.45。
- 3个月随访时2例(3.4%)复发,均经第二次微波消融成功处理;仅1例(1.7%)出现轻微并发症,无严重并发症。
核心结论
- CT引导经皮微波消融是治疗骨样骨瘤的一种微创、高效且安全的方法。
研究设计与样本
- 单中心回顾性研究,纳入2021年1月至2023年5月连续59例接受经皮CT引导微波消融治疗的骨样骨瘤患者,评估临床与影像特征、手术数据、VAS疼痛评分、并发症发生率及临床和技术成功率。
诊断标准与关键数值
- 3个月随访时复发2例(3.4%),均经第二次微波消融成功处理。
- VAS疼痛评分中位数从术前8.64±1.14降至术后第1个月0.63±0.98、第3个月0.41±1.02、第6个月0.15±0.45。
- 轻微并发症1例(1.7%),无严重并发症。
临床应用与阅片要点
- 原文结论认为CT引导经皮微波消融是治疗骨样骨瘤的微创、高效且安全的方法。
- 术后VAS疼痛评分在随访期内持续低于术前。
- 3个月随访时2例(3.4%)复发,均经第二次微波消融成功处理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: The aim of the current study was to evaluate the feasibility and effectiveness of CT-guided microwave ablation (MWA) in the treatment of osteoid osteomas (OO).
MATERIALS AND METHODS: Data from 59 consecutive patients who underwent percutaneous CT-MWA for OO treatment were examined in the current retrospective study. The period of this study spanned from January 2021 to May 2023 at a single institution. The study involved an evaluation of clinical and radiological characteristics, procedural data, Visual Analog Scale (VAS) pain scores, complication incidences, as well as clinical and technical success rates. Statistical analyses were performed by using the Wilcoxon test with Bonferroni correction, Friedman, Spearman, Mann-Whitney U test.
RESULTS: 59 patients with an average age of 17.31 ± 8.53 years underwent CT-guided MWA for the treatment of OO. The procedure demonstrated a high success rate, with 96.6% of cases achieving both technical and clinical success. However, recurrence was observed in two patients (3.4%) at the three-month follow-up. These cases were successfully managed with a second MWA procedure. The median VAS pain scores reported by the patients was significantly improved post-procedure: from 8.64 ± 1.14 before treatment to 0.63 ± 0.98 in the first month, 0.41 ± 1.02 in the third month, and 0.15 ± 0.45 in the sixth month. Only one patient (1.7%) experienced a minor complication; no major complications were recorded in this study.
CONCLUSION: CT-guided percutaneous MWA is a minimally invasive and a highly effective and safe approach for the treatment of OO.
引用
- Mutlu IN, Cingoz M, Guzelbey T, et al. Percutaneous CT-Guided Microwave Ablation for the Treatment of Osteoid Osteomas: A Single Center Experience. Acad Radiol. 2024. PMID: 38490842. doi:10.1016/j.acra.2024.02.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。